CMS has set a device intensive status for the procedure, meaning the total cost of the device is included in the reimbursement rate for ASCs, according to a March 9 press release by Gynesonics.
The reimbursement for ASCs will be $3,632.42 for the transcervical uterine fibroid ablation. For Sonata procedures performed in a hospital outpatient setting, ambulatory payment classification has increased to $6,794.31.
More articles on physicians:
There were 226 ASCs opened in 2019 & 3 more MedPAC 2021 report highlights
Missouri medical group breaks ground on outpatient surgery center
Bundled payments in ASCs: Good business or a race to the bottom?
